Boit C F David Has $4.61 Million Holdings in Stryker Corporation $SYK

Boit C F David increased its holdings in shares of Stryker Corporation (NYSE:SYK) by 1.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,645 shares of the medical technology company’s stock after buying an additional 200 shares during the quarter. Stryker accounts for approximately 2.2% of Boit C F David’s holdings, making the stock its 17th largest holding. Boit C F David’s holdings in Stryker were worth $4,607,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in Stryker by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock worth $12,306,572,000 after buying an additional 361,136 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Stryker by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock worth $4,515,847,000 after buying an additional 1,021,496 shares during the period. Goldman Sachs Group Inc. raised its stake in Stryker by 13.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock worth $838,640,000 after buying an additional 261,058 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Stryker by 4.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,086,960 shares of the medical technology company’s stock worth $776,871,000 after buying an additional 83,954 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in Stryker by 1.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,015,374 shares of the medical technology company’s stock worth $750,223,000 after buying an additional 30,329 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In other news, insider Viju Menon sold 500 shares of the firm’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is owned by company insiders.

Stryker Price Performance

Shares of NYSE SYK opened at $379.96 on Wednesday. The stock has a market capitalization of $145.26 billion, a price-to-earnings ratio of 50.33, a PEG ratio of 2.75 and a beta of 0.94. The business has a 50-day moving average of $379.56 and a 200-day moving average of $379.10. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating the consensus estimate of $3.07 by $0.06. The company had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.Stryker’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, sell-side analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker’s dividend payout ratio (DPR) is presently 44.50%.

Analyst Ratings Changes

Several analysts recently commented on the company. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research note on Saturday. Truist Financial dropped their price target on Stryker from $415.00 to $407.00 and set a “hold” rating on the stock in a research note on Wednesday, October 15th. Evercore ISI dropped their price target on Stryker from $418.00 to $410.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 7th. Rothschild & Co Redburn began coverage on Stryker in a research note on Thursday, September 18th. They issued a “neutral” rating and a $420.00 price target on the stock. Finally, BTIG Research lifted their price target on Stryker from $407.00 to $408.00 and gave the company a “buy” rating in a research note on Monday, October 13th. Fifteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average price target of $431.76.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.